The year 2017 might be coming to a close, but research continues to ramp up at Children’s Hospital of Philadelphia, with exciting developments in the fields of brain science, hemophilia, gene therapy, and more. In this week’s roundup of headlines, we take a look at remarkable reports from CHOP and Penn Medicine about the brain’s ability to reorganize itself after limb amputation, the first U.S. effort to observe the use of medical cannabis for children with autism, and exciting innovations to improve sickle cell disease treatment presented at the 59th American Society of Hematology Annual Meeting and Exposition. Read on to discover more about these brilliant breakthroughs.
Tag Archive: sickle cell disease
Notable awards, new autism initiatives, and a novel approach to managing sickle cell disease are all part of this week’s roundup of research news.
Investigators at The Children’s Hospital of Philadelphia are exploring a new gene therapy approach that aims to reactivate the production of fetal hemoglobin as a potential intervention for patients with sickle cell disease.
Kelly A. Dougherty, PhD recently received an award from the NIH that will support her investigation of vitamin A supplementation and sickle cell disease.
Hematologists have long sought to reactivate fetal hemoglobin as a treatment for children and adults with sickle cell disease (SCD). Researchers at CHOP have manipulated key biological events in adult blood cells to produce a form of hemoglobin normally absent after the newborn period.
Sickle cell disease affects millions of people worldwide and is the most common inherited disorder in African Americans, of whom 1 in 375 is born with the disease.
In a recent interview with the National Initiative for Children’s Healthcare Quality (NICHQ), Kwaku Ohene-Frempong, MD, Doctor Emeritus of CHOP’s Comprehensive Sickle Cell Center, discussed his work with sickle cell disease.